Early Screening Markers of Herpes Zoster Neuralgia

NCT ID: NCT07038707

Last Updated: 2025-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Herpes zoster (HZ), especially postherpetic neuralgia, is one of the most typical types of clinical neuralgia. The incidence rate of HZ in China is approximately 7.7%. Among them, 29.8% of HZ patients eventually develop PHN. About 20% of PHN patients suffer from severe neuralgia for more than one year, or even ten years. It is worth noting that patients with neuralgia are prone to comorbidities such as depression, anxiety and sleep disorders, which seriously affect their work efficiency and quality of life. This is a great torment to both the patients and their families, and it also imposes a heavy burden on the medical system.

Professor Xiao Lizu, a collaborator of our team, has discovered in clinical practice that spinal cord electrical stimulation for HZ patients can significantly reduce the risk of developing PHN. Other therapies for reducing the risk of PHN include multiple parvertebral injections of local anesthetics/steroids, which require patients to return for repeated visits. Although these intervention measures have good effects, they may bring additional economic burdens to patients, treatment side effects and prolong their hospital stays. Therefore, they are not suitable for all patients. From this perspective, our development of early screening methods and selective non-pharmacological intervention only for high-risk patients will improve the overall treatment status of HZ, effectively reduce the incidence of PHN, and alleviate the burden on medical insurance and the medical system at the same time.

This project aims to conduct the following research by analyzing the intestinal flora of patients: identifying biomarkers with the ability to predict the risk of PHN in patients, constructing a machine learning classifier for risk prediction, and developing an early screening kit based on this.

Furthermore, traditional studies mostly focus on a single pathological link and lack systematic multi-dimensional analysis. In recent years, the cerebral lymphatic system, as a key pathway for the clearance of metabolic wastes in the brain, has attracted widespread attention. Furthermore, the role of the gut-brain axis in pain regulation has gradually been recognized. Therefore, it is of great scientific significance to integrate and explore the pathological mechanism of PHN from three dimensions: the lymphatic system, neuroinflammation, and intestinal flora.

This project assumes that patients with PHN have a pathological triad of "lymphoid dysfunction - neuroinflammatory activation - intestinal flora imbalance". The specific manifestations are as follows: Impaired lymphoid clearance function (decreased DTI-ALPS index and increased free water), activated systemic inflammatory response (elevated TNF-α and IL-6), and disordered intestinal flora structure (decreased α diversity and increased opportunistic pathogenic bacteria). The three interact with each other and have a synergistic effect, jointly participating in the pathogenesis of PHN.The expected outcome of this project may provide new options for pain management of the large group of neuralgia patients, improve their quality of life, and has great practicality and practical value.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postherpetic Neuralgia ( PHN ) Lymphatic System Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy control group

Healthy individuals matched by age and gender (without a history of HZ or chronic pain diseases).

Extract the serum and feces of the patients for standard screening of early biomarkers

Intervention Type OTHER

In this study, blood and fecal samples from patients with herpes and herpes neuralgia were collected for genomic sequencing of the gut microbiota and metabolome analysis, etc. Based on the principle of diffusion tensor imaging, by measuring the anisotropic diffusion of white matter around the corpus callosum at the horizontal level of the lateral ventricle body, the lymphatic system clearance function is quantified

Meningeal lymphatic vessel imaging

Intervention Type OTHER

The functional changes of the cerebral lymphatic system in patients with PHN were detected by meningeal lymphatic vessel imaging

PHN Group

Individuals among patients with herpes zoster (HZ) who eventually develop PHN (according to the diagnostic criteria of PHN, such as persistent pain for ≥3 months)

Extract the serum and feces of the patients for standard screening of early biomarkers

Intervention Type OTHER

In this study, blood and fecal samples from patients with herpes and herpes neuralgia were collected for genomic sequencing of the gut microbiota and metabolome analysis, etc. Based on the principle of diffusion tensor imaging, by measuring the anisotropic diffusion of white matter around the corpus callosum at the horizontal level of the lateral ventricle body, the lymphatic system clearance function is quantified

Meningeal lymphatic vessel imaging

Intervention Type OTHER

The functional changes of the cerebral lymphatic system in patients with PHN were detected by meningeal lymphatic vessel imaging

HZ did not convert to the PHN group

Individuals among patients with herpes zoster who did not develop PHN (with complete remission of pain within 3 months).

Extract the serum and feces of the patients for standard screening of early biomarkers

Intervention Type OTHER

In this study, blood and fecal samples from patients with herpes and herpes neuralgia were collected for genomic sequencing of the gut microbiota and metabolome analysis, etc. Based on the principle of diffusion tensor imaging, by measuring the anisotropic diffusion of white matter around the corpus callosum at the horizontal level of the lateral ventricle body, the lymphatic system clearance function is quantified

Meningeal lymphatic vessel imaging

Intervention Type OTHER

The functional changes of the cerebral lymphatic system in patients with PHN were detected by meningeal lymphatic vessel imaging

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extract the serum and feces of the patients for standard screening of early biomarkers

In this study, blood and fecal samples from patients with herpes and herpes neuralgia were collected for genomic sequencing of the gut microbiota and metabolome analysis, etc. Based on the principle of diffusion tensor imaging, by measuring the anisotropic diffusion of white matter around the corpus callosum at the horizontal level of the lateral ventricle body, the lymphatic system clearance function is quantified

Intervention Type OTHER

Meningeal lymphatic vessel imaging

The functional changes of the cerebral lymphatic system in patients with PHN were detected by meningeal lymphatic vessel imaging

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The definite diagnoses were PHN (disease course ≤ 1 month), PHN (1 month \< disease course \< 2 months), and PHN (disease course \> 3 months); Age equal to 50 years old; Not accompanied by other chronic pain diseases; Sign the informed consent form.

Exclusion Criteria

* There are underlying digestive system diseases such as irritable bowel syndrome and inflammatory bowel disease; There are obvious gastrointestinal discomfort symptoms such as diarrhea and abdominal distension; There is immunosuppression or autoimmune disease; Antibiotics, acid suppressants or drugs that interfere with the intestinal flora have been used within the past month; Have a history of mental illness or abuse of tobacco and alcohol (2 packs per day)
Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tongji Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xuebi Tian

Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TJ-IRB20250519

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pathophysiological Study of the Sensitive Scalp
NCT07156422 NOT_YET_RECRUITING NA